Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BioDelivery Sciences International on the deal while Troutman Pepper advised Collegium Pharmaceutical. BioDelivery Sciences International (NASDAQ: BDSI) announced its definitive merger agreement to be...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Cerevel Therapeutics on the deal. Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters on the deal, while Dechert advised Femasys. Chardan, a global investment bank, announced that it acted as lead left bookrunner in...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised HiFiBiO on the deal. HiFiBiO announced its oversubscribed $75 million Series D financing round. HiFiBiO is a multinational biotechnology company with unique expertise...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Hogan Lovells and Cooley advised Valneva. Gide advised Goldman Sachs, Jefferies,...
You must be a Standard 1 Year member to access this content.
